Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery

NCT01606735 is registered in ClinicalTrials.gov with ICON Bioscience Inc as lead sponsor.

NCT NCT01606735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01606735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery
Lead sponsor
ICON Bioscience Inc
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
March 31, 2013
Enrollment
172 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation associated with cataract surgery